Escherichia coli GutM4 produces 2,5-diketopiperazines and inhibits human pathogens in vitro
Background: It has been a very common practice to use probiotics or their metabolites as alternative antimicrobial strategies for the treatment and prevention of infections as rampant and indiscriminate use of antibiotics causes the development of antibiotic-resistant pathogens. The objective of thi...
Main Authors: | Xichun Zhang, Junmin Du, Yu Wang, Shuming Chen, Yingli Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-07-01
|
Series: | Electronic Journal of Biotechnology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0717345817300210 |
Similar Items
-
Diketopiperazine from marine bacterium Pseudoalteromonas ruthenica KLPp3
by: Faiq Sulieman, et al.
Published: (2018-05-01) -
An Update on 2,5-Diketopiperazines from Marine Organisms
by: Ri-Ming Huang, et al.
Published: (2014-12-01) -
A facile synthesis of cysteine-based diketopiperazine from thiol-protected precursor
by: Di Zhang, et al.
Published: (2018-01-01) -
In vivo characterization of the activities of novel cyclodipeptide oxidases: new tools for increasing chemical diversity of bioproduced 2,5-diketopiperazines in Escherichia coli
by: Fabien Le Chevalier, et al.
Published: (2020-09-01) -
A New Prenylated Indole Diketopiperazine Alkaloid from Eurotium cristatum
by: Xianwei Zou, et al.
Published: (2014-11-01)